Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Irwin

Showing results (71-80 of 100) with videos related to

Pageof 10
Sort By:
Current Oncology (Toronto, Ont.)|April 27, 2026
Percutaneous Image-Guided Non-Target Renal Biopsy in Cancer Patients: A Tertiary Cancer Center ExperienceMohamed E Abdelsalam, Milan N Patel, Ryan D Murray, et al.
The New England Journal of Medicine|June 27, 2003
A phase 2 study of bortezomib in relapsed, refractory myelomaPaul G Richardson, Bart Barlogie, James Berenson, et al.
Annals of Neurology|June 16, 2025
Blood α-Synuclein Separates Parkinson's Disease from Dementia with Lewy BodiesGeorge T Kannarkat, Rebecca Zack, R Tyler Skrinak, et al.
Research Square|October 7, 2024
α-Synuclein Conformations in Plasma Distinguish Parkinson's Disease from Dementia with Lewy BodiesGeorge T Kannarkat, Rebecca Zack, R Tyler Skrinak, et al.
Biorxiv : the Preprint Server for Biology|May 20, 2024
α-Synuclein Conformations in Plasma Distinguish Parkinson's Disease from Dementia with Lewy BodiesGeorge T Kannarkat, Rebecca Zack, R Tyler Skrinak, et al.
NPJ Parkinson'S Disease|June 2, 2022
Quantitative detection of α-Synuclein and Tau oligomers and other aggregates by digital single particle countingLara Blömeke, Marlene Pils, Victoria Kraemer-Schulien, et al.
Neurocase|May 17, 2024
Symptomatic progression of frontotemporal dementia with the <i>TARDBP</i> I383V variantPeter S Pressman, Danelle J Carter, Eliana Marisa Ramos, et al.
Annals of Neurology|March 18, 2026
Association between Plasma P-tau217 and Alzheimer's Copathology and Cognitive Decline in Parkinson's DiseaseThomas F Tropea, Patricia Aldea Stevenson, Matthew Flitter, et al.
Blood|August 11, 2007
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trialPaul G Richardson, Pieter Sonneveld, Michael Schuster, et al.
The New England Journal of Medicine|June 17, 2005
Bortezomib or high-dose dexamethasone for relapsed multiple myelomaPaul G Richardson, Pieter Sonneveld, Michael W Schuster, et al.
Pageof 10

Showing results (71-80 of 100) with videos related to

Sort By:
Pageof 10
Current Oncology (Toronto, Ont.)|April 27, 2026
Percutaneous Image-Guided Non-Target Renal Biopsy in Cancer Patients: A Tertiary Cancer Center ExperienceMohamed E Abdelsalam, Milan N Patel, Ryan D Murray, et al.
The New England Journal of Medicine|June 27, 2003
A phase 2 study of bortezomib in relapsed, refractory myelomaPaul G Richardson, Bart Barlogie, James Berenson, et al.
Annals of Neurology|June 16, 2025
Blood α-Synuclein Separates Parkinson's Disease from Dementia with Lewy BodiesGeorge T Kannarkat, Rebecca Zack, R Tyler Skrinak, et al.
Research Square|October 7, 2024
α-Synuclein Conformations in Plasma Distinguish Parkinson's Disease from Dementia with Lewy BodiesGeorge T Kannarkat, Rebecca Zack, R Tyler Skrinak, et al.
Biorxiv : the Preprint Server for Biology|May 20, 2024
α-Synuclein Conformations in Plasma Distinguish Parkinson's Disease from Dementia with Lewy BodiesGeorge T Kannarkat, Rebecca Zack, R Tyler Skrinak, et al.
NPJ Parkinson'S Disease|June 2, 2022
Quantitative detection of α-Synuclein and Tau oligomers and other aggregates by digital single particle countingLara Blömeke, Marlene Pils, Victoria Kraemer-Schulien, et al.
Neurocase|May 17, 2024
Symptomatic progression of frontotemporal dementia with the <i>TARDBP</i> I383V variantPeter S Pressman, Danelle J Carter, Eliana Marisa Ramos, et al.
Annals of Neurology|March 18, 2026
Association between Plasma P-tau217 and Alzheimer's Copathology and Cognitive Decline in Parkinson's DiseaseThomas F Tropea, Patricia Aldea Stevenson, Matthew Flitter, et al.
Blood|August 11, 2007
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trialPaul G Richardson, Pieter Sonneveld, Michael Schuster, et al.
The New England Journal of Medicine|June 17, 2005
Bortezomib or high-dose dexamethasone for relapsed multiple myelomaPaul G Richardson, Pieter Sonneveld, Michael W Schuster, et al.
Pageof 10